108
+1.89%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ReproCell
Its shares trade on Tokyo Stock Exchange under the ticker 4978.T. It has been listed since 26 June 2013. In the fiscal year to 31 March 2026, it reported revenue of ¥2.23bn and a net loss of ¥591.7m. At that date it held total assets of ¥9.65bn and shareholders' equity of ¥8.85bn.
ReproCELL Inc. engages in stem cell research. The company is headquartered in Yokohama, Kanagawa-Ken. The company went IPO on 2013-06-26. The firm operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Jun 2013
- Employees
- 111
- Website
- reprocell.co.jp ↗
Leadership
Pay as last reported
- Mr. Chikafumi YokoyamaPresident, Chairman of Subsidiaries, Representative Director, since 2011
- Mr. Satoshi MunemuraChief Financial Officer, General Manager of Business Administration Unit
- Mr. Daisuke UsuiChief Operating Officer, Director, since 2020
- Mr. Shigetomo AkanoDirector, since 2020
- Mr. Yoshiyuki YamakawaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ReproCell Inc has a strong reputation in the industry for its high-quality products and services, which has enabled the company to build a loyal customer base.
- The company has a robust research and development team, enabling it to continuously innovate and stay ahead of competitors.
- ReproCell Inc has established strong partnerships with key industry players, allowing it to access new markets and expand its customer base.
Weaknesses
- One of the weaknesses of ReproCell Inc is its limited geographical presence, as it primarily operates in a few regions. This puts the company at a disadvantage compared to competitors with a broader global reach.
- The company heavily relies on a few key customers for a significant portion of its revenue, making it vulnerable to any changes in their demands or business situations.
- ReproCell Inc has faced challenges in scaling its production capacity to meet increasing demand, which has led to occasional supply chain disruptions.
Opportunities
- There is a growing global demand for regenerative medicine and stem cell research, presenting significant opportunities for ReproCell Inc to expand its market share.
- The company can explore untapped geographical markets by establishing partnerships or opening new branches in regions where it currently has a limited presence.
- ReproCell Inc can diversify its product and service offering to cater to a wider range of customer needs, such as introducing new technologies or expanding into related fields.
Threats
- The competitive landscape in the regenerative medicine industry is intense, with several established players and new entrants vying for market share. This poses a threat to ReproCell Inc's market position.
- Changes in regulations and policies related to stem cell research and regenerative medicine can significantly impact ReproCell Inc's operations and restrict its ability to expand or operate in certain markets.
- The ongoing COVID-19 pandemic has disrupted supply chains and impacted the overall demand for medical products and services, including those offered by ReproCell Inc.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.